Equity Overview
Price & Market Data
Price: $3.70
Daily Change: -$0.37 / 10.00%
Daily Range: $3.61 - $4.17
Market Cap: $725,258,048
Daily Volume: 6,621,088
Performance Metrics
1 Week: -1.60%
1 Month: -18.94%
3 Months: 159.2%
6 Months: 37.31%
1 Year: -18.22%
YTD: 26.03%
Company Details
Employees: 214
Sector: Health technology
Industry: Biotechnology
Country:
Details
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.